Haptoglobulin for Use in Treating or Preventing Exaggerated Erectile Response or Erectile Dysfunction
AssigneeCSL Behring GmbH
InventorsFábio Henrique Da Silva, Fernando Ferreira Costa
Life of this patent
Estimating the term…
Abstract
The invention relates to haptoglobin or a nucleic acid encoding haptoglobin for use in treating or preventing of exaggerated erectile response and/or preventing permanent erectile dysfunction. In addition, the invention relates a pharmaceutical composition for use in treating or preventing exaggerated erectile response and/or preventing permanent erectile dysfunction, wherein the pharmaceutical composition comprises an adeno-associated viral (AAV) vector with a transgene encoding a haptoglobin gene. The exaggerated erectile response may be priapism, for example priapism associated with sickle cell disease (SCD).
Claims16
A method of treating or preventing exaggerated erectile response and/or preventing permanent erectile dysfunction, comprising administering a haptoglobulin or a nucleic acid encoding haptoglobin to a subject.
A method of treating or preventing exaggerated erectile response and/or preventing permanent erectile dysfunction, comprising administering a pharmaceutical composition to a subject, wherein the pharmaceutical composition comprises an adeno-associated viral (AAV) vector with a transgene encoding a haptoglobin gene.
Dependencies are inferred from the claim text.